Bergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
Hox Therapeutics has announced the appointment of Dr Karl Keegan as Chief Executive Officer.
Oxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
Zelluna Immunotherapy has announced the appointment of Geir Christian Melen as chief financial officer (CFO).
Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
Exscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
Pfizer Inc. today announced its Board of Directors has unanimously elected Dr. Albert Bourla, 56, Pfizer Chief Operating Officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will transition from his current role as Chairman and CEO to Executive Chairman of Pfizer’s Board of Directors.
Ysios Capital, a biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal.
Virion Biotherapeutics announced the appointments of Vanessa King, PhD, as President & Chief Executive Officer this week.
Ascelia Pharma announced on Friday Spetember 14 that Carl Bjartmar, MD, PhD, has been appointed as new Chief Medical Officer (CMO) for Ascelia Pharma. Carl has most recently worked as CMO for Wilson Therapeutics.